Evaluation of cardiovascular ischemic event rates in
dasatinib-treated patients using standardized incidence ratios

J 2017

Evaluation of cardiovascular ischemic event rates in dasatinib-treated patients using standardized incidence ratios

SAGLIO, Giuseppe, Philipp le COUTRE, Jorge CORTES, Jiří MAYER, Philip ROWLINGS et. al.

Základní údaje

Originální název

Evaluation of cardiovascular ischemic event rates in dasatinib-treated patients using standardized incidence ratios

Autoři

SAGLIO, Giuseppe (380 Itálie), Philipp le COUTRE (276 Německo), Jorge CORTES (840 Spojené státy), Jiří MAYER (203 Česká republika, garant, domácí), Philip ROWLINGS (36 Austrálie), Francois Xavier MAHON (250 Francie), Glenn KROOG (840 Spojené státy), Kyna GOODEN (840 Spojené státy), Milayna SUBAR (840 Spojené státy) a Neil P. SHAH (840 Spojené státy)

Vydání

Annals of hematology, Berlin, Springer Verlag, 2017, 0939-5555

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30205 Hematology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 2.845

Kód RIV

RIV/00216224:14110/17:00098740

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1007/s00277-017-3012-z

UT WoS

000404207100007

Klíčová slova anglicky

Chronic myeloid leukemia; Tyrosine kinase inhibitors; Dasatinib; Cardiovascular; Ischemic

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 20. 3. 2018 17:50, Soňa Böhmová

Anotace

V originále

With high survival rates for chronic myeloid leukemia (CML) patients treated with BCR-ABL1 tyrosine kinase inhibitors (TKIs), emerging consequences, such as arterial ischemic events, require consideration when evaluating treatment options. Cardiovascular ischemic event incidence in clinical trials was evaluated in 2712 dasatinib-treated patients with Philadelphia chromosome-positive (Ph+) leukemias from 11 first- and second-line trials (pooled), newly diagnosed CML patients treated with dasatinib or imatinib (DASISION), and prostate cancer patients treated with dasatinib or placebo plus docetaxel/prednisone (READY). Overall, 2-4% of dasatinib-treated patients had cardiovascular ischemic events. Most dasatinib-treated patients with an event had a history of and/or risk factor for atherosclerosis (pooled 77 with history/risk and event/96 with events; DASISION 8/10; READY 15/18). Most cardiovascular ischemic events occurred within 1 year of initiating dasatinib (pooled 69/96; DASISION 7/10; READY 16/18). Comparison of observed and expected event rates through standardized incidence ratios indicates that dasatinib does not increase risk for cardiovascular ischemic events compared with external reference populations.

Citovat

SAGLIO, Giuseppe, Philipp le COUTRE, Jorge CORTES, Jiří MAYER, Philip ROWLINGS, Francois Xavier MAHON, Glenn KROOG, Kyna GOODEN, Milayna SUBAR a Neil P. SHAH. Evaluation of cardiovascular ischemic event rates in dasatinib-treated patients using standardized incidence ratios. Annals of hematology. Berlin: Springer Verlag, 2017, roč. 96, č. 8, s. 1303-1313. ISSN 0939-5555. Dostupné z: https://dx.doi.org/10.1007/s00277-017-3012-z.

@article{1399038,
   author = {Saglio, Giuseppe and Coutre, Philipp le and Cortes, Jorge and Mayer, Jiří and Rowlings, Philip and Mahon, Francois Xavier and Kroog, Glenn and Gooden, Kyna and Subar, Milayna and Shah, Neil P.},
   article_location = {Berlin},
   article_number = {8},
   doi = {http://dx.doi.org/10.1007/s00277-017-3012-z},
   keywords = {Chronic myeloid leukemia; Tyrosine kinase inhibitors; Dasatinib; Cardiovascular; Ischemic},
   language = {eng},
   issn = {0939-5555},
   journal = {Annals of hematology},
   title = {Evaluation of cardiovascular ischemic event rates in dasatinib-treated patients using standardized incidence ratios},
   volume = {96},
   year = {2017}
}

TY  - JOUR
ID  - 1399038
AU  - Saglio, Giuseppe - Coutre, Philipp le - Cortes, Jorge - Mayer, Jiří - Rowlings, Philip - Mahon, Francois Xavier - Kroog, Glenn - Gooden, Kyna - Subar, Milayna - Shah, Neil P.
PY  - 2017
TI  - Evaluation of cardiovascular ischemic event rates in dasatinib-treated patients using standardized incidence ratios
JF  - Annals of hematology
VL  - 96
IS  - 8
SP  - 1303-1313
EP  - 1303-1313
PB  - Springer Verlag
SN  - 09395555
KW  - Chronic myeloid leukemia
KW  - Tyrosine kinase inhibitors
KW  - Dasatinib
KW  - Cardiovascular
KW  - Ischemic
N2  - With high survival rates for chronic myeloid leukemia (CML) patients treated with BCR-ABL1 tyrosine kinase inhibitors (TKIs), emerging consequences, such as arterial ischemic events, require consideration when evaluating treatment options. Cardiovascular ischemic event incidence in clinical trials was evaluated in 2712 dasatinib-treated patients with Philadelphia chromosome-positive (Ph+) leukemias from 11 first- and second-line trials (pooled), newly diagnosed CML patients treated with dasatinib or imatinib (DASISION), and prostate cancer patients treated with dasatinib or placebo plus docetaxel/prednisone (READY). Overall, 2-4% of dasatinib-treated patients had cardiovascular ischemic events. Most dasatinib-treated patients with an event had a history of and/or risk factor for atherosclerosis (pooled 77 with history/risk and event/96 with events; DASISION 8/10; READY 15/18). Most cardiovascular ischemic events occurred within 1 year of initiating dasatinib (pooled 69/96; DASISION 7/10; READY 16/18). Comparison of observed and expected event rates through standardized incidence ratios indicates that dasatinib does not increase risk for cardiovascular ischemic events compared with external reference populations.
ER  -

SAGLIO, Giuseppe, Philipp le COUTRE, Jorge CORTES, Jiří MAYER, Philip ROWLINGS, Francois Xavier MAHON, Glenn KROOG, Kyna GOODEN, Milayna SUBAR a Neil P. SHAH. Evaluation of cardiovascular ischemic event rates in dasatinib-treated patients using standardized incidence ratios. \textit{Annals of hematology}. Berlin: Springer Verlag, 2017, roč.~96, č.~8, s.~1303-1313. ISSN~0939-5555. Dostupné z: https://dx.doi.org/10.1007/s00277-017-3012-z.

Podrobný výpis o publikaci